Elysium Health
| Company type | Private |
|---|---|
| Industry | Dietary supplements, Life sciences |
| Founded | 2014 |
| Founder | Leonard Guarente, Dan Alminana, Eric Marcotulli |
| Headquarters | New York City , United States |
| Products | Basis, Index, Matter, Format, Mosaic, Vision |
| Website | elysiumhealth |
Elysium Health is a U.S.-based producer of dietary supplements, headquartered in New York City.
History
Established in 2014 by Leonard Guarente, Dan Alminana, and Eric Marcotulli, Elysium introduced its inaugural product, Basis, in 2015. Basis features nicotinamide riboside and pterostilbene, formulated to promote anti-aging effects.
In December 2016, the company raised $20 million through a Series B funding round. By 2019, Elysium had launched Index, an epigenetic test using saliva samples to estimate biological age.
The product range grew with the release of Matter in June 2020, which focuses on preserving cognitive health and decelerating brain aging. Later, in October 2021, Format was introduced to enhance immune system support and address aging concerns.
In 2023, Elysium unveiled Mosaic, a daily supplement purported to protect collagen and delay skin aging. The subsequent year saw the debut of Vision, targeting eye health and macular longevity.
Litigation
Initially, Elysium obtained the ingredients for Basis from ChromaDex, which supplied these materials to multiple supplement manufacturers as of December 2016. The companies had an arrangement permitting Elysium to omit crediting ChromaDex as the source. However, after recruiting ChromaDex’s VP of business development and allegedly stopping payments, ChromaDex initiated legal action against Elysium, bringing the conflict into public view.
In September 2018, both Dartmouth College and ChromaDex filed suit against Elysium alleging patent infringement related to nicotinamide riboside. In August 2020, W.R. Grace and Company also pursued litigation over patent violations concerning crystalline nicotinamide riboside. By September 2021, a U.S. district court judge dismissed the claims from Dartmouth and ChromaDex, ruling their patents invalid.
The decision was upheld in February 2023 by the United States Court of Appeals for the Federal Circuit, which confirmed that the patent infringement allegations failed under 35 U.S.C. § 101.